An irresolute linker: separation, and structural and spectroscopic characterization of the two linkage isomers of a Ru(ii)-(2-(2'-pyridyl)pyrimidine-4-carboxylic acid) complex.

For the first time the two linkage isomers of a Ru(ii) complex with 2-(2'-pyridyl)pyrimidine-4-carboxylic acid (cppH) - that form in comparable amounts - have been fully characterized individually. The X-ray structure of each isomer is related to its NMR spectrum in solution.

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

The influence of chemical stability on the antimetastatic ruthenium(III) compound imidazolium trans-imidazoletetrachlorodimethylsulphoxideruthenium(III) (NAMI-A) in aqueous solution was studied both in vitro and in vivo. The loss of dimethyl-sulphoxide (DMSO) ligand from the compound was tested by using a NAMI-A solution acidified with HCl at pH 3.0 and aged for 0, 4, 8 and 24 h prior to intraperitoneal (i.p.) injection into CBA mice bearing advanced MCa mammary carcinoma. The activity of NAMI-A on lung metastases showed no change even after the loss of DMSO ligand from up to 50% of the molecules. The reduction of NAMI-A did not modify the number of KB cells blocked in the S+G2M phases, independent of whether the reduction occurred outside the cells or after loading the cells with the compound prior to treatment with the reductants (ascorbic acid, glutathione or cysteine). In vivo, the complete reduction of NAMI-A with equivalent amounts of ascorbic acid, glutathione or cysteine prior to administration to mice bearing advanced MCa mammary carcinoma was more active than NAMI-A alone. The data show that NAMI-A, although undergoing a series of chemical modifications, maintains its antimetastatic activity in a broad range of experimental conditions.

Photophysics of pyridylporphyrin Ru(II) adducts: heavy-atom effects and intramolecular decay pathways.

Eight adducts between different pyridylporphyrins and ruthenium complexes, MPyP[RuCl(2)(DMSO)(2)(CO)], c-DPyP[RuCl(2)(DMSO)(2)(CO)](2), TrPyP[RuCl(2)(DMSO)(2)(CO)](3), TPyP[RuCl(2)(DMSO)(2)(CO)](4), (MPyP)(2)[RuCl(2)(DMSO)(2)], [c-DPyP[RuCl(2)(DMSO)(2)]](2), MPyP[RuCl(2)(CO)(3)], and [c-DPyP[RuCl(2)(CO)(2)]](2), have been investigated. The results show that in all the adducts the porphyrin singlet is quenched, to a greater or lesser extent, relative to the parent-free molecule. This study provides insight into the mechanisms of singlet quenching in the adducts. Two mechanisms for singlet quenching, both related to the "heavy-atom effect" of the ruthenium center and experimentally distinguishable by transient spectroscopy, are examined. Enhanced intersystem crossing within the porphyrin chromophore is demonstrated for the series of adducts MPyP[RuCl(2)(DMSO)(2)(CO)], c-DPyP[RuCl(2)(DMSO)(2)(CO)](2), TrPyP[RuCl(2)(DMSO)(2)(CO)](3), and TPyP[RuCl(2)(DMSO)(2)(CO)](4), where a nice correlation is observed between the magnitude of the effect and the number of ruthenium centers attached to the pyridylporphyrin chromophore. Singlet-triplet energy transfer from the pyridylporphyrin chromophore to the ruthenium center(s) is an additional efficient quenching channel for adducts containing ruthenium centers with weak field ligands and low triplet energies, such as (MPyP)(2)[RuCl(2)(DMSO)(2)] and [c-DPyP[RuCl(2)(DMSO)(2)]](2).

Novel Unsymmetrical Ru(III) and Mixed-valence Ru(III)/Ru(II) Dinuclear Compounds Related to the Antimetastatic Ru(III) Drug NAMI-A.

In this paper we report the stepwise preparation and the characterization of new unsymmetrical monoanionic Ru(III) dinuclear compounds, [NH(4)][{trans-RuCl(4)(Me(2)SO-S)}(mu-L){mer-RuCl(3)(Me(2)SO-S)(Me(2)SO-O)}] (L = pyz (1), pym (2)). By a similar synthetic approach we also prepared new mixed-valence Ru(III)/Ru(II) dinuclear compounds of formula [NH(4)][{trans-RuCl(4)(Me(2)SO-S)}(mu-pyz){cis,cis,cis-RuCl(2)(Me(2)SO-S)(2)(CO)}] (L = pyrazine (pyz, 3), pyrimidine (pym, 4)). Moreover, we describe the chemical behavior of compounds 1-4 in physiological solution, also after complete reduction (with ascorbic acid) to the corresponding Ru(II)/Ru(II) species. Overall, the chemical behavior of 1 and 2 after reduction resembles that of the corresponding dianionic and neutral dinuclear species, [{trans-RuCl(3)(Me(2)SO-S)}(2)(mu-L)](2-)and [{mer-RuCl(3)(Me(2)SO-S)(Me(2)SO-O)}(2) (mu-L)]. On the other hand, the mixed-valence dinuclear compounds 3 and 4, owing to the great inertness of the cis,cis,cis-RuCl(2)(Me(2)SO-S)(2)(CO)(1/2mu-L) fragment, behave substantially like the mononuclear species [trans-RuCl(4)(Me(2)SO-S)(L)](-) in which the terminally bonded L ligand can be considered as bearing a bulky substituent on the other N atom.

Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.

The ruthenium complexes trans-dichlorotetrakisdimethylsulfoxide ruthenium(II) (trans-Ru), imidazolium trans-imidazoletetrachlororuthenate (ICR), sodium trans-tetramethylensulfoxideisoquinolinetetrachlororuthenate (TEQU), and imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate (NAMI-A) are tested in vitro by short exposure of MCF-7, LoVo, KB, and TS/A tumor cells to 10(-4) M concentration, and in vivo on Lewis lung carcinoma by a daily i.p. treatment for 6 consecutive days using equitoxic and maximum tolerated doses. NAMI-A 1) inhibited tumor cell invasion of matrigel, 2) induced a transient accumulation of cells in the G(2)-M phase, 3) did not modify in vitro cell growth, and 4) markedly reduced lung metastasis formation. TEQU showed significant cytotoxicity in vitro and was not antimetastatic in vivo. ICR and trans-Ru did not modify cell cycle distribution of in vitro tumor cells nor did they inhibit matrigel invasion; ICR was also devoid of antimetastasis effects in vivo. Ruthenium uptake by tumor cells did account for in vitro cytotoxicity but not for other in vitro actions or for in vivo antimetastasis activity. The contemporary absence of cytotoxicity, associated to inhibition of matrigel crossing and to transient block in the premitotic G(2)-M phase, appears to be prerequisites for a ruthenium compound to show in vivo-selective antimetastasis effect. The validation of this model for other classes of compounds will allow an understanding of the combined weight of the above-mentioned phenomena for tumor metastasis growth and control.

Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.

A series of three ruthenium complexes, i.e. trans-dichlorote-trakisdimethyl-sulfoxide ruthenium(ll) (trans-Ru), imidazolium trans-imidazoletetra-chlororuthenate (ICR) and sodium trans-tetramethylensulfoxideisoquinoline-tetrachlororuthenate (TEQU), were studied in vitro in comparison to NAMI-A, a potent ruthenium-based antimetastasis agent. In vitro challenge of TS/A adenocarcinoma or KB oral carcinoma tumor cells with 10(-4) M concentration for 1 h evidenced the lack of cytotoxicity of NAMI-A, ICR and trans-Ru, the accumulation of cells in the G2/M pre-mitotic cell phase by NAMI-A and the attachment of tumor cells to the plastic substrate was significantly greater for NAMI-A than for ICR. These data stress that in vitro cytotoxicity is not necessary for in vivo activity of ruthenium antitumor complexes: NAMIA, ICR and trans-Ru, are in fact known to be active against murine tumors in the mouse system. Rather, TEQU, the compound free of in vivo activity, was the only one to reduce cell growth of in vitro cultured cells. In conclusion, the data on the effects of NAMI-A on in vitro cultured cells show that the increase of cell adhesion properties and the transient cell cycle arrest in the G2/M phase are much more relevant than the effects on cell properties relevant to cell growth (i.e. on CD44, CD54 or CD71 antigens) for determining in vivo antimetastasis activity.

Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.

A novel class of dianionic Ru(III) dimers of formula Na2[[trans-RuCl4(Me2SO)]2(mu-L)], with L = pyrazine (pyz, 1), pyrimidine (pym, 2), 4,4'-bipyridine (bipy, 3), and 1,2-bis(4-pyridine) ethane (etbipy, 4), was developed by us with the specific aim of assessing their antitumor properties. The dimers are in fact structurally related to the antimetastatic mononuclear compound (ImH) [trans-RuCl4(Me2SO)(Im)] (NAMI-A, Im = imidazole). Preliminary results concerning the antineoplastic activity of 1-4 against the murine MCa carcinoma model, a tumor which spontaneously metastasizes in the lungs, are reported. Similarly to what is normally observed with NAMI-A, the treatment with the dimeric complexes was scarcely effective against the growth of the primary tumor. However, dimers 1, 2, and 4 reduced very effectively the number and, in particular, the weight of lung metastases (to about 5% with respect to controls); in particular, Na2[[trans-RuCl4(Me2SO)]2(mu-etbipy)] (4) was as effective as NAMI-A in reducing the spontaneous metastases at a dosage which, in terms of moles of ruthenium, is about 3.5 times lower compared to that normally used for NAMI-A. Furthermore, in vitro tests showed that dimers 1-4 are capable of forming interstrand cross-links with linearized plasmidic DNA in a time-dependent manner. All the dimeric species are more active in inducing cross-links compared to NAMI-A, and the dimer bridged by the etbipy ligand (4) is the most effective among those tested.

A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.

The reaction of Na[transRuCl4Me2SO(Im)] (NAMI; where Im is imidazole), a novel anti-neoplastic ruthenium(III) complex, with BSA, was studied in detail by various physico-chemical techniques. It is shown that NAMI, following chloride hydrolysis, binds bovine serum albumin tightly; spectrophotometric and atomic absorption data point out that up to five ruthenium ions are bound per albumin molecule when BSA is incubated for 24 h with an eightfold excess of NAMI. CD and electronic absorption results show that the various ruthenium centers bound to albumin exhibit well distinct spectroscopic features. The first ruthenium equivalent produces a characteristic positive CD band at 415 nm whereas the following NAMI equivalents produce less specific and less marked spectral effects. At high NAMI/BSA molar ratios a broad negative CD band develops at 590 nm. Evidence is provided that the bound ruthenium centers remain in the oxidation state +3. By analogy with the case of transferrins it is proposed that the BSA-bound ruthenium ions are ligated to surface histidines of the protein; results from chemical modification experiments with diethylpyrocarbonate seem to favor this view. Spectral patterns similar to those shown by NAMI are observed when BSA is reacted with two strictly related ruthenium(III) complexes Na[transRuCl4(Me2SO)2] and H(Im)[transRuCl4(Im)2] (ICR), implying a similar mechanism of interaction in all cases. It is suggested that the described NAMI-BSA adducts may form in vivo and may be relevant for the biological properties of this complex; alternatively NAMI/BSA adducts may be tested as specific carriers of the ruthenium complex to cancer cells. Implications of these findings for the mechanism of action of NAMI and of related ruthenium(III) complexes are discussed.

Understanding the orientation and dynamic motion of planar heterocyclic N-donor ligands by exploiting the symmetry properties of mixed-ligand mu-oxorhenium(V) dinuclear complexes.

Factors influencing the orientation and dynamic motions of planar N-donor heterocyclic ligands (L) are of interest since such features have broad relevance in metallobiochemistry [Marzilli, L. G.; Marzilli, P. A.; Alessio, E. Pure Appl. Chem. 1998, 70, 961-968]. We found that mu-oxorhenium(V) dinuclear complexes [ReOCl2LsLt]-O-[ReOCl2LsLt] bearing either symmetrical (L = py = pyridine; 3,5-lut = 3,5-lutidine) or lopsided (L = Me3-Bzm = 1,5,6-trimethylbenzimidazole) cis L ligands are particularly useful for studying these factors. NMR data showed that terminal (Lt) and stacked (Ls) ligands were exchanged by approximately 180 degrees rotation about the Re-O-Re bond system. Such exchange occurred, however, between degenerate chiral conformers. Here we report a combined X-ray structural and solution NMR investigation of the AA + CC (racemic) and AC (meso) forms of two mixed-ligand mu-oxorhenium dimers that bear one lopsided and one symmetrical ligand on each Re atom, namely, Re2O3-Cl4(py)2(Me3Bzm)2 (1rac and 1meso) and Re2O3Cl4(3,5-lut)2(Me3Bzm)2 (2rac and 2meso). The presence of two different cis L ligands in 1 and 2 breaks the local symmetry at each Re atom, so that, in the racemic dimers, the exchange of terminal and stacked ligands leads to nondegenerate conformers. Overall, NMR data showed that the unsymmetrical dimers 1 and 2 undergo two dynamic processes contemporaneously, namely, 180 degrees rotation about the Re-N(py or 3,5-lut) bond and coupled rotation about the Re-O-Re/Re-N bonds. Both processes reach the slow exchange limit below -80 degrees C. Rotation of py in 1 occurs faster than that of 3,5-lut in 2; this difference is attributed to the higher steric demands of 3,5-lut compared to py. For both dimers NMR data provided compelling evidence of the preferred conformers in solution, including ligand orientations. The low-T solution structure of 1meso and 2meso is chiral, the same as that found in the solid state for 2meso, where the Me3Bzm on one Re atom is stacked with the 3,5-lut on the other Re atom. The remaining Me3Bzm and 3,5-lut, one on each Re atom, are both terminal. In solution the coupled Re-O-Re/Re-N rotations interconvert the two halves of each meso dimer to yield the same overall stable chiral conformation. For the racemic dimers, however, this process does not interconvert one enantiomer into the other, but instead interconverts two rotamers, R1 and R2, each of which is chiral. We found that, in the case of both 1rac and 2rac, the conformer with stacking symmetrical ligands (R1) is roughly 1 order of magnitude more stable than that with stacking Me3Bzm ligands (R2). Moreover, the solution conformation of R1 is the same as that found in the solid state of 1rac. Solution- and solid-state data indicate that the key interaction favoring the observed conformations is very likely the electrostatic attraction between the delta+ H2 atoms on the Me3Bzm ligands and the negative O and Cl groups in the core of the dimers. Finally, for both meso and racemic dimers we were also able to elucidate the preferred pathways of the coupled dynamic motions and establish that, very likely, the two halves of the dimers swing back and forth by approximately 130 degrees through the anti eclipsed form.

Stepwise assembly of unsymmetrical supramolecular arrays containing porphyrins and coordination compounds.

The stepwise coordination of meso-4'-pyridyl/phenyl porphyrins (4'-PyPs) to different metal centers proved to be an efficient synthetic approach leading to unsymmetrical arrays containing porphyrins and coordination compounds. The first step of this process, treatment of 4'-PyPs with a less than stoichiometric amount of cis,fac-RuCl2(Me2-SO)3(CO) (1), leads to the selective coordination of [cis,cis,cis-RuCl2(Me2SO)2(CO)] fragments ([Ru]) to some of the peripheral 4'-N sites of the 4'-PyPs. Column separation afforded four partially ruthenated 4'-PyPs in pure form: 4'-cis-DPyP[Ru] (2), 4'-trans-DPyP[Ru] (3), (4'-TPyP)[Ru] (4), and (4'-TPyP)[Ru]3 (5). These compounds, which have residual unbound peripheral 4'-N(py) sites (either one or three), were allowed to react with other metal centers that may belong either to a metalloporphyrin or to a coordination compound. When building blocks 2-5 were treated with [Ru(TPP)(CO)(EtOH)] (TPP = meso-tetraphenylporphyrin) in chloroform at room temperature, axial coordination of Ru(TPP)(CO) units ((Ru)) to the available 4'-N(py) sites readily occurred, generating the following arrays containing both perpendicular porphyrins and coordination compounds: (Ru)-(mu-4'-cis-DPyP)[Ru], (Ru)(mu-4'-trans-DPyP)[Ru], (Ru)3(mu-4'-TPyP)[Ru], and (Ru)(mu-4'-TPyP)[Ru]3. Furthermore, building blocks 2, 3, and 5 were treated with a series of coordination compounds capable of binding two pyridylporphyrins either cis to each other (trans-RuCl2(Me2SO)4 and trans,cis,cis-RuCl2(Me2SO)2(CO)2) or trans to each other (trans-PdCl2(C6H5CN)2). Homo- (Ru) and heterobimetallic (Ru-Pd) arrays with as many as seven metal atoms (six Ru and one Pd) and two 4'-PyPs were obtained as follows: trans,cis,cis-RuCl2(Me2SO)2(4'-cis-DPyP[Ru])2, trans,cis,cis-RuCl2(Me2SO)2(4'-trans-DPyP[Ru])2, trans,cis,cis-RuCl2(CO)2(4'-cis-DPyP[Ru])2, and trans-PdCl2(4'-TPyP[Ru]3)2. All the products were thoroughly characterized by 1H NMR spectroscopy. Since the [Ru] fragment is chiral, diastereomers are formed when two or more [Ru] units are bound to a porphyrin. We found that when two 4'-cis-DPyP[Ru] (2) units are coordinated cis to each other on the same metal center, the mutual anisotropic effect of the cis porphyrins differentiates the sulfoxide methyl resonances for the two forms. These and other results indicate that the pyridyl units react independently of the presence or absence of a substituent on the other py rings. Thus, the synthetic strategy should be a general method for linking diverse metal centers through pyridylporphyrins.